DDIT3 and diffuse large B-cell lymphoma: In the past two decades, a great deal of effort has been devoted to improving the clinical outcome of R-CHOP as the frontline treatment for DLBCL, including shortening the interval between treatment cycles, intensifying the treatment, or incorporating new drugs alongside R-CHOP.